Chapter 6: The COVID-19 Evidence Accelerator


  1. Evidence Accelerator Home | Evidence Accelerator. Accessed January 12, 2022.
  2. Real-World Data Webinar Series: Data Standards | Reagan-Udall Foundation. Accessed January 12, 2022.
  3. Learn about Friends of Cancer Research. Accessed January 12, 2022.
  4. Parallel Analysis Workgroup | Evidence Accelerator. Accessed January 12, 2022.
  5. Stewart M, Rodriguez-Watson C, Albayrak A, et al. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. Di Gennaro F, ed. PLoS ONE. 2021;16(3):e0248128. doi:10.1371/journal.pone.0248128
  6. Chakravarty A, Roe L, Lasky T, et al. Generating Actionable Insights from Real-World Data -- The Covid-19 Evidence Accelerator.
  7. Diagnostics Parallel Analysis Workgroup | Evidence Accelerator. Accessed January 12, 2022.
  8. Rodriguez-Watson C, McGraw D, Garner C, Greene S. Getting Real About Data Sharing for Drug Development and Drug Safety: What COVID-19 is Teaching us About the Possibilities and How to Move From Anomaly to Precedent; DIA Virtual Global Annual Meeting, 2020.
  9. Data Sources for Post-Authorization Safety Studies. In: Post-Authorization Safety Studies of Medicinal Products. Elsevier; 2018:49-103. doi:10.1016/B978-0-12-809217-0.00003-9
  10. Devoe JE, Gold R, McIntire P, Puro J, Chauvie S, Gallia CA. Electronic health records vs Medicaid claims: completeness of diabetes preventive care data in community health centers. Ann Fam Med. 2011;9(4):351-358. doi:10.1370/afm.1279
  11. Ehrenstein V, Kharrazi H, Lehmann H, et al. Obtaining Data From Electronic Health Records. In: Gliklich RE, Leavy MB, Dreyer NA, editors. Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User’s Guide, 3rd Edition, Addendum 2 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Oct. Chapter 4. Available from: